In a research report released this morning, Cantor analyst Daniel Brims reiterated a Buy rating on shares of Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), with a …
In a research report published today, Cantor analyst Daniel Brims reiterated a Buy rating on shares of Endocyte, Inc. (NASDAQ:ECYT) with a price target …
In a research report published Wednesday, Cantor analyst Daniel Brims reiterated a Buy rating on shares of MEI Pharma Inc (NASDAQ:MEIP), with a price …
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) received another set of praises from analysts at Cantor in a research note released yesterday.
Cantor analyst Daniel Brims was out pounding the table on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Thursday, reiterating a Buy rating and price target of $14, …
The first quarter of 2015 has come to a close and companies are still releasing earnings reports. Let’s look back and see which …
Cantor’s healthcare analyst Daniel Brims came out with a few insights on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), after the company hosted an Analyst and Investor Day on April …
The investment firm Cantor Fitzgerald lowered its price target today on MEI Pharma Inc (NASDAQ:MEIP) to $7.00 (from $14.
Cantor’s healthcare analyst Daniel Brims weighed in today with an optimistic view on MEI Pharma Inc (NASDAQ:MEIP), after the company's cancer drug failed to meet the main goal …
Cantor analyst Daniel Brims was out pounding the table on Endocyte, Inc. (NASDAQ:ECYT), reiterating an Outperform rating and a $21.
